Literature DB >> 24637921

HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data.

Sabrina Hense1, Kathrin Hillebrand1, Johannes Horn2, Rafael Mikolajczyk2, Renate Schulze-Rath3, Edeltraut Garbe4.   

Abstract

In Germany, vaccination against human papilloma virus (HPV) has been recommended by the German Standing Vaccination Committee (STIKO) for girls aged 12-17 years since March 2007. The vaccine is free of charge for this age group. Additionally, some statutory health insurance providers (SHI) offer reimbursement for women aged 18-26 years. Currently available information on the uptake or coverage of HPV vaccination is limited to specific regions, age groups, or study populations. This report describes the HPV vaccine uptake in 2008 for females aged 12-26 years in Germany on a broad regional level based on data from one large SHI. HPV vaccinations were identified by outpatient codes used for reimbursement of vaccine administration. Vaccine uptake was calculated by dividing the number of females, who received at least one HPV vaccine dose by the number of female insurees in the respective age group. The overall study population consisted of 317 234 females, of whom 77 350 received at least one HPV vaccine dose in 2008. Vaccine uptake was 32.2% in the recommended age group, with a peak age at 14-16 years. In the age group of females aged 18-26 years, where HPV vaccination was not officially recommended by the STIKO, uptake was 12.3%. Vaccine uptake in 2008 reflects an early stage after the recommendation of HPV vaccination in 2007. Future changes in vaccine uptake should be further and more promptly monitored.

Entities:  

Keywords:  claims data; females; human papilloma virus; uptake; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24637921      PMCID: PMC5396220          DOI: 10.4161/hv.28450

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  25 in total

1.  The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.

Authors:  F Dorleans; C Giambi; L Dematte; S Cotter; P Stefanoff; J Mereckiene; D O'Flanagan; P L Lopalco; F D'Ancona; D Levy-Bruhl
Journal:  Euro Surveill       Date:  2010-11-25

2.  School-based vaccination in NSW.

Authors:  Kirsten F Ward; Robert I Menzies; Helen E Quinn; Sue Campbell-Lloyd
Journal:  N S W Public Health Bull       Date:  2010 Sep-Oct

3.  HPV infection awareness and self-reported HPV vaccination coverage in female adolescent students in two German cities.

Authors:  F Samkange-Zeeb; L Spallek; S J Klug; H Zeeb
Journal:  J Community Health       Date:  2012-12

4.  NSW annual immunisation coverage report, 2011.

Authors:  Brynley Hull; Aditi Dey; Sue Campbell-Lloyd; Robert I Menzies; Peter B McIntyre
Journal:  N S W Public Health Bull       Date:  2012-12

5.  Human Papillomavirus awareness, knowledge and vaccine acceptance: a survey among 18-25 year old male and female vocational school students in Berlin, Germany.

Authors:  Susanne Blödt; Christine Holmberg; Jacqueline Müller-Nordhorn; Nina Rieckmann
Journal:  Eur J Public Health       Date:  2011-12-23       Impact factor: 3.367

6.  Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010.

Authors:  Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson
Journal:  Cancer       Date:  2012-11-26       Impact factor: 6.860

7.  HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey.

Authors:  Yvonne Deleré; Merle M Böhmer; Dietmar Walter; Ole Wichmann
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

8.  Validity of reported vaccination coverage in 45 countries.

Authors:  Christopher J L Murray; Bakhuti Shengelia; Neeru Gupta; Saba Moussavi; Ajay Tandon; Michel Thieren
Journal:  Lancet       Date:  2003-09-27       Impact factor: 79.321

9.  Factors determining vaccine uptake in Western Australian adolescents.

Authors:  Donna B Mak; Max K Bulsara; Megan J Wrate; Dale Carcione; Melissa Chantry; Paul V Efller
Journal:  J Paediatr Child Health       Date:  2012-12-02       Impact factor: 1.954

10.  Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-07-26       Impact factor: 17.586

View more
  3 in total

1.  Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.

Authors:  Kathrin Thöne; Johannes Horn; Rafael Mikolajczyk
Journal:  BMC Infect Dis       Date:  2017-08-14       Impact factor: 3.090

2.  Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017.

Authors:  Miriam Reuschenbach; Sarah Mihm; Regine Wölle; Kim Maren Schneider; Christian Jacob; Sebastian Braun; Wolfgang Greiner; Monika Hampl
Journal:  BMC Infect Dis       Date:  2020-04-22       Impact factor: 3.090

3.  Pneumococcal vaccination coverage in individuals (16-59 years) with a newly diagnosed risk condition in Germany.

Authors:  Arijita Deb; Bélène Podmore; Rosemarie Barnett; Dominik Beier; Wolfgang Galetzka; Nawab Qizilbash; Dennis Haeckl; Timo Boellinger; Kelly D Johnson; Thomas Weiss
Journal:  BMC Infect Dis       Date:  2022-09-28       Impact factor: 3.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.